Disc Medicine, Inc. (NASDAQ: IRON) announced the pricing of an upsized underwritten offering of common stock and pre-funded warrants, with gross proceeds expected to be approximately $225 million for Disc and $25 million for the Selling Stockholder. The proceeds will support potential commercialization of bitopertin for EPP and XLP, research, clinical development, and general corporate purposes. The offering is expected to close on October 22, 2025, with Jefferies, Leerink Partners, Morgan Stanley, and Cantor acting as joint book-running managers. The offering is made pursuant to automatic shelf registration statements on Form S-3.

Read more at GlobeNewswire: Disc Medicine Announces Pricing of $250 Million Upsized